Breast cancer prevention with anti-estrogens: review of the current evidence and future directions

@article{Mallick2015BreastCP,
  title={Breast cancer prevention with anti-estrogens: review of the current evidence and future directions},
  author={Supriya Mallick and Rony Benson and Pramod Kumar Julka},
  journal={Breast Cancer},
  year={2015},
  volume={23},
  pages={170-177}
}
There is a potential for reducing the incidence of breast cancer by modifying or changing the reversible risk factors like dietary modifications, modifications in the sedentary life habits, etc. One of such methods which has gained popularity now is chemoprevention. Many agents have been evaluated in the chemoprevention setting in females with increased risk of breast cancers. Metformin, NSAIDS, Bisphosphonates, and statins were evaluated by various investigators with variable results. One of… 

Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial.

Positive changes in menopause-specific QOL influence a woman's decision to stop chemoprevention therapy and attention to such symptoms may improve QOL and potentially improve chemoparevention adherence.

Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report

The need to screen breast cancer patients for the possibility of an AEWE if they are using raloxifene and possibly similar selective estrogen receptor modulators (SERMs) which includes tamoxifen, when diagnosed with advanced breast cancer, especially in the recurrent disease setting is highlighted.

Decision making for breast cancer prevention among women at elevated risk

This article reviews the existing research on the uptake of these prevention approaches, the characteristics of women who are likely to use various methods, and the decision-making processes that underlie the differing choices of women, and highlights important areas for future research.

Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762

It is suggested that the striking effects of I-BET 762 are the result of targeting both tumor cells and the tumor microenvironment, and not only induced growth arrest and downregulated c-Myc, pSTAT3, and pERK protein expression in tumor cells in vitro and in vivo but also altered immune populations in different organs.

Disease Subtype–Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A

WA is a promising chemopreventative phytochemical with the ability to inhibit at least two different subtypes of breast cancer.

Risk Assessment for Sporadic Breast Cancer : The Need for a Molecular Profile

Observations support the feasibility and encourage efforts to develop a molecular profile of normal breast tissue for breast cancer risk assessment in women.

Cancer Progress and Priorities: Breast Cancer

Survival has increased over the past few decades, with the introduction of screening mammography and improved treatments, however, progress has not been seen equally among all ethnicities/races or with all breast cancer subtypes (e.g., triple negative).

New benzothienopyrimidine derivatives as dual EGFR/ARO inhibitors: Design, synthesis, and their cytotoxic effect on MCF‐7 breast cancer cell line

New cytotoxic agents based on benzothienopyrimidine scaffold were designed, synthesized, and evaluated against the MCF‐7 breast cancer line in comparison to erlotinib and letrozole as reference drugs to demonstrate higher anticancer activity and a fivefold higher selectivity index.

Case Carcinoma Breast

The chapter aims to summarize the case taking and examination in patients with carcinoma breast and how to derive a treatment plan for patients with cancer.

References

SHOWING 1-10 OF 39 REFERENCES

Aromatase inhibitors for breast cancer prevention.

  • J. Cuzick
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
The third-generation aromatase inhibitors (AIs) have been introduced into the treatment of breast cancer, and their greater efficacy compared to tamoxifen, along with a more favorable side-effect profile, make them attractive agents for use in breast cancer prevention.

Use of bisphosphonates and risk of postmenopausal breast cancer.

The use of bisphosphonates for longer than 1 year was associated with a 28% relative reduction in the risk of postmenopausal breast cancer.

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

A 0.5-mg dose of lasofoxifene appears to reduce the risks of both total and ER+ invasive breast cancer in postmenopausal women with osteoporosis.

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

Among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during 3 years of treatment with raloxifene, mainly in the United States and Europe.

Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer

A decreased risk of breast cancer was observed in female patients with type 2 diabetes using metformin on a long-term basis, and neither short-term met formin use nor use of sulfonylureas or other antidiabetes drugs was associated with a materially altered risk for breast cancer.

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.

The prophylactic effect of tamoxifen was fairly constant for the entire follow-up period, and no diminution of benefit was observed for up to 10 years after randomization, but side effects in the tamoxIFen group were much lower after completion of the active treatment period than during active treatment.

Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies.

The meta-analysis findings do not support a protective effect of statins against breast cancer, and further studies are required to investigate the potential decrease in breast cancer risk among long-term statin users.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Despite the potential bias caused by the unblinding of the P-1 trial, the magnitudes of all beneficial and undesirable treatment effects of tamoxifen were similar to those initially reported, with notable reductions in breast cancer and increased risks of thromboembolic events and endometrial cancer.

Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women

Like other SERMs, arzoxifene decreased vertebral fractures and invasive breast cancer while the risk of venous thromboembolic events increased.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.